Juvenile Psoriatic Arthritis;Enthesitis Related Arthritis

Drug: Ixekizumab;Drug: Adalimumab

Criteria for participation in trial

Inclusion Criteria:

- Participants must have active juvenile idiopathic arthritis (categories of enthesitis
related arthritis or juvenile psoriatic arthritis)

- Participants must have weight of at least 10 kilograms (Kg), age starting at 2 years
for participants with juvenile psoriatic arthritis and starting at 6 years for
participants with enthesitis related arthritis

- Participants must have all immunizations up-to-date in agreement with current
immunization guidelines, in the opinion of the investigator

Exclusion Criteria:

- Participants must not have active or history of inflammatory bowel disease

- Participants must not have active uveitis

- Participants must not have active or latent tuberculosis

- Participants must not have an active infection

- Participants must not have concurrent use of biologic agents for the treatment of the
juvenile idiopathic arthritis

Carcinoma, Non- Small Cell Lung

Drug: Durvalumab;Other: Placebo

Criteria for participation in trial

Inclusion Criteria:

1. Capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the ICFs and in the protocol.

2. Age =18 years at the time of screening (ICF1);

3. Histologically confirmed NSCLC with resectable stage II-III disease

4. Complete resection of the primary NSCLC

Exclusion Criteria:

1. EGFR and/or ALK mutant

2. Mixed small cell and NSCLC histology

3. History of allogeneic organ or bone marrow transplantation

4. History of active primary immunodeficiency

Plaque Psoriasis;Psoriasis Vulgaris;Psoriasis

Biological: Brodalumab;Other: Placebo;Biological: Guselkumab

Criteria for participation in trial

Key Inclusion Criteria:

- Participant has a diagnosis of plaque psoriasis for at least 6 months before the first
administration of investigational medicinal product (IMP) as determined by the
investigator.

- Participant has inadequately controlled plaque psoriasis currently treated with
ustekinumab, and fulfil ALL of the following criteria:

1. Ustekinumab administered at least 3 times at or higher than the approved dose or
frequency for at least 24 weeks.

2. IGA =2 at screening and baseline.

3. Absolute PASI >3 at screening and baseline.

4. The last administration of ustekinumab was =12 weeks before randomisation.

- Participant has no active tuberculosis at screening (negative QuantiFERON® or purified
protein derivative [PPD] test). Participants with adequately treated latent
tuberculosis are eligible.

Key Exclusion Criteria:

- Participant was diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate
psoriasis, medication-induced psoriasis, or other skin conditions (e.g. eczema) that
would interfere with evaluations of the effect of IMP on plaque psoriasis.

- Participant has clinically important active infections or infestations, chronic,
recurrent, or latent infections or infestations, or is immunocompromised (e.g. human
immunodeficiency virus).

- Participant has any systemic disease (e.g. renal failure, heart failure, hypertension,
liver disease, diabetes, anaemia) considered by the investigator to be clinically
significant and uncontrolled.

- Participant has a known history of Crohn's disease.

- Participant has any active malignancy, including evidence of cutaneous basal or
squamous cell carcinoma or melanoma.

- Participant has a history of malignancy within 5 years, except for treated and
considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer,
or in situ breast ductal carcinoma.

- Participant has a known history of active tuberculosis.

- Participant has a history of suicidal behaviour (i.e. 'actual suicide attempt',
'interrupted attempt', 'aborted attempt', or 'preparatory acts or behaviour') based on
the Columbia-Suicide Severity Rating Scale (C-SSRS) questionnaire at screening or
baseline.

- Participant has any suicidal ideation of severity 4 or 5 ('some intent to act, no
plan' or 'specific plan and intent') based on the C-SSRS questionnaire at screening or
baseline.

- Participant has a Patient Health Questionnaire-8 (PHQ-8) score of =10, corresponding
to moderate to severe depression at screening or baseline.

- Participant has previously received more than 1 tumour necrosis factor a (TNF a)
inhibitor.

- Participant has previously been treated with any anti-interleukin (IL)-17A, anti-IL 17
receptor subunit A, or anti-IL-23 besides ustekinumab.

- Participant has known or suspected hypersensitivity to any component(s) of the IMPs.